2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Futibatinib and Binimetinib - Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Taiho Oncology, Inc. | 38 | 2021-09-20 | 2024-09-19 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Everolimus (1) · binimetinib (1) · futibatinib (1) · neratinib (1) · palbociclib (1) · trametinib (1)
M.D. Anderson Cancer Center (1) · Taiho Oncology, Inc. (1)
United States (2)